Reyvow (lasmiditan) - Eli Lilly, Daiichi Sankyo, Organon
Reyvow: Protection of compound patent in US/Japan until 2028 (Eli Lilly) - Mar 6, 2025 - Annual Report 2024: Regulatory data protection in EU/Japan until 2032 
Commercial • Patent CNS Disorders • Migraine • Pain
https://investor.lilly.com/static-files/5c870f9a-45f1-4da1-b2cc-4fd18ff6e82b
 
Mar 6, 2025
 
 
f43a11df-fbe2-4d68-ad78-204c660da4c2.png